Aliases & Classifications for Burns

Summaries for Burns

MedlinePlus : 43 A burn is damage to your body's tissues caused by heat, chemicals, electricity, sunlight, or radiation. Scalds from hot liquids and steam, building fires and flammable liquids and gases are the most common causes of burns. Another kind is an inhalation injury, caused by breathing smoke. There are three types of burns: First-degree burns damage only the outer layer of skin Second-degree burns damage the outer layer and the layer underneath Third-degree burns damage or destroy the deepest layer of skin and tissues underneath Burns can cause swelling, blistering, scarring and, in serious cases, shock, and even death. They also can lead to infections because they damage your skin's protective barrier. Treatment for burns depends on the cause of the burn, how deep it is, and how much of the body it covers. Antibiotic creams can prevent or treat infections. For more serious burns, treatment may be needed to clean the wound, replace the skin, and make sure the patient has enough fluids and nutrition. NIH: National Institute of General Medical Sciences

MalaCards based summary : Burns is related to glossitis and vulvar vestibulitis syndrome. An important gene associated with Burns is TTR (Transthyretin), and among its related pathways/superpathways are Aldosterone synthesis and secretion and MAPK signaling pathway. The drugs silver nitrate and Bacitracin have been mentioned in the context of this disorder. Affiliated tissues include Umbilical Cord, skin and eye, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and hematopoietic system

Related Diseases for Burns

Diseases related to Burns via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 622)
# Related Disease Score Top Affiliating Genes
1 glossitis 32.3 IL1B TTR
2 vulvar vestibulitis syndrome 31.7 IL1B TNF
3 complex regional pain syndrome 31.6 IL1B TNF
4 pyelonephritis 30.8 ALB IL1B TNF
5 toxic shock syndrome 30.4 IL1B SERPINC1 TNF
6 chronic ulcer of skin 30.3 ALB TTR
7 compartment syndrome 30.2 ALB TNF
8 staphylococcal toxic shock syndrome 30.1 IL1B TNF
9 laryngitis 30.1 IL1B TNF
10 trichosporonosis 30.0 CSF2 TNF
11 decubitus ulcer 29.9 ALB TTR
12 irritant dermatitis 29.9 IL1B TNF
13 euthyroid sick syndrome 29.7 ALB IL1B
14 aphthous stomatitis 29.6 IL1B TNF
15 protein-energy malnutrition 29.3 ALB TNF TTR
16 respiratory failure 29.2 ALB TNF TTR
17 lung disease 29.2 CSF2 IL1B TNF
18 meningitis 29.2 ALB IL1B TNF
19 peritonitis 29.0 ALB IL1B TNF
20 autonomic nervous system disease 28.5 ALB INS TTR
21 duodenal ulcer 28.5 IL1B INS TNF
22 diabetes mellitus 27.7 ALB IL1B INS TNF
23 asthma 27.0 CRH CSF2 IL1B INS TNF
24 burning mouth syndrome 12.4
25 burn-mckeown syndrome 12.4
26 burning mouth syndrome type 3 12.1
27 burn scar 12.1
28 partial deep dermal and full thickness burns 12.0
29 burn goodship syndrome 11.9
30 choanal atresia-hearing loss-cardiac defects-craniofacial dysmorphism syndrome 11.7
31 orofaciodigital syndrome iv 11.3
32 erythermalgia, primary 11.2
33 trigeminal neuralgia 11.1
34 glossodynia 11.1
35 herpes zoster 11.1
36 reflex sympathetic dystrophy 11.1
37 erythromelalgia 11.1
38 paresthesia 11.1
39 peripheral nervous system disease 11.1
40 polyneuropathy 11.1
41 causalgia 11.1
42 fabry disease 11.1
43 restless legs syndrome 11.1
44 mental retardation, x-linked, syndromic 13 11.0
45 hypertrophic scars 11.0
46 severe cutaneous adverse reaction 11.0
47 lichen planus 11.0
48 paine syndrome 10.9
49 cellulitis 10.9
50 oral submucous fibrosis 10.9

Graphical network of the top 20 diseases related to Burns:



Diseases related to Burns

Symptoms & Phenotypes for Burns

GenomeRNAi Phenotypes related to Burns according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.8 CSF2 INS TNF

MGI Mouse Phenotypes related to Burns:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.87 HGF IL1B INS SERPINC1 TNF CRH
2 homeostasis/metabolism MP:0005376 9.86 IL1B INS SERPINC1 ALB TNF CRH
3 cardiovascular system MP:0005385 9.85 CSF2 HGF IL1B INS SERPINC1 TNF
4 liver/biliary system MP:0005370 9.63 HGF INS SERPINC1 ALB TNF CRH
5 no phenotypic analysis MP:0003012 9.35 HGF INS TNF CRH TTR
6 renal/urinary system MP:0005367 9.02 INS SERPINC1 ALB CRH CSF2

Drugs & Therapeutics for Burns

Drugs for Burns (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 988)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 silver nitrate Approved, Investigational Phase 4,Phase 3,Phase 2
2
Bacitracin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1405-87-4 439542 10909430
3
Bronopol Approved Phase 4,Phase 3,Phase 2 52-51-7
4
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-23-7 5754
5 Parthenolide Approved, Investigational Phase 4,Phase 3 20554-84-1
6
Carboprost Tromethamine Approved Phase 4 58551-69-2 5284525 45266502
7
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 1 113775-47-6 68602 5311068
8
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 51-43-4 5816
9
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 137-58-6 3676
10
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 329-65-7 838
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 437-38-7 3345
12
Chlorhexidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 55-56-1 9552079 2713
13
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 22916-47-8 4189
14
Fluticasone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2 90566-53-3 62924
15
Benzoyl peroxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-36-0 7187
16
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Phase 2 18323-44-9 29029
17
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106-60-5 137
18
Adapalene Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 106685-40-9 60164
19
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
20
Donepezil Approved Phase 4,Phase 3,Phase 2 120014-06-4 3152
21
Midazolam Approved, Illicit Phase 4,Phase 2,Not Applicable 59467-70-8 4192
22
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
23
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
24
Chlorthalidone Approved Phase 4 77-36-1 2732
25
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
26
Silver sulfadiazine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 22199-08-2 441244
27
Sulfadiazine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 68-35-9 5215
28
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
29
Metronidazole Approved Phase 4,Phase 2,Phase 3,Not Applicable 443-48-1 4173
30
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 9004-61-9 53477741
31
Pioglitazone Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 111025-46-8 4829
32
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 299-42-3 9294
33
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90-82-4 7028
34
Hydrogen peroxide Approved, Vet_approved Phase 4,Not Applicable 7722-84-1 784
35
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 124-94-7 31307
36
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75614-87-8, 51-45-6 774
37
Hydroxocobalamin Approved Phase 4,Phase 3,Not Applicable 13422-51-0 11953898 44475014
38
Benzydamine Approved Phase 4,Phase 3,Phase 1 100-46-9, 642-72-8 7504
39
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 564-25-0 54671203
40
Minocycline Approved, Investigational Phase 4,Not Applicable 10118-90-8 5281021
41
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
42
Povidone-iodine Approved Phase 4,Not Applicable 25655-41-8
43
Ethanol Approved Phase 4,Phase 3,Phase 1,Early Phase 1,Not Applicable 64-17-5 702
44
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Not Applicable 85721-33-1 2764
45
Petrolatum Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 8009-03-8
46
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
47
Iron Approved Phase 4,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
48
Vancomycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 1404-90-6 441141 14969
49
Iodine Approved, Investigational Phase 4,Phase 2,Not Applicable 7553-56-2 807
50
Povidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 9003-39-8

Interventional clinical trials:

(show top 50) (show all 1963)
# Name Status NCT ID Phase Drugs
1 Hypoalbuminemia in Burn Patients Unknown status NCT01436292 Phase 4 5% human albumin solution (HAS)
2 Early Fluid Resuscitation With Balanced HES 130/0.4 [6%] in Severe Burn Injury Unknown status NCT01012648 Phase 4 Fluid resuscitation;HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution
3 Computerized Counseling to Promote Positive Prevention and HIV Health in Kenya Unknown status NCT01015989 Phase 4
4 The Treatment of Bartholin´s Cyst or Abscess With Silver Nitrate Unknown status NCT00786461 Phase 4
5 Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents Unknown status NCT01797562 Phase 4 T.R.U.E. Test Panel 3.2
6 Evaluate the Efficacy, Safety and Tolerability of a Non-hormonal Intravaginal Gel in Postmenopausal Women With Symptoms of Vaginal Dryness. Unknown status NCT02571127 Phase 4 Hidra1
7 Dexmedetomidine on Prevention of Side Effects of Hemabate Unknown status NCT02220361 Phase 4 placebo;low dose dexmedetomidine;high dose dexmedetomidine
8 TRPV Expression in Subjects With Sensitive Skin Unknown status NCT01871883 Phase 4
9 Intranasal Fentanyl for Pain Management Unknown status NCT00882960 Phase 4 intravenous fentanyl;intra-nasal fentanyl
10 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
11 Trial on the Efficacy of Tegaderm Chlorhexidine Gluconate (CHG) in Reducing Catheter Related Bloodstream Infections Unknown status NCT01142934 Phase 4
12 Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
13 Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris Unknown status NCT01448733 Phase 4 Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
14 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
15 Pilot Study of Tolerability and Effectivity of Two Combination Topical Acne Products Unknown status NCT02731105 Phase 4 Acnatac® Gel left face;Epiduo® Gel right face;Acnatac® Gel right face;Epiduo® Gel left face
16 Postoperative Pain and Angiotensin II Receptor Antagonists Unknown status NCT02513979 Phase 4 Angiotensin type II receptor antagonists
17 CALM-AD Unknown status NCT00142324 Phase 4 Donepezil
18 The Effect of High-dose Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers (HighDose RemiSun) Unknown status NCT01015482 Phase 4 Remifentanil;Midazolam
19 The Effect of Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers Unknown status NCT00811837 Phase 4 Midazolam;Remifentanil
20 Management of Chronic Pain in Military Patients With Injuries Sustained During Active Duty Unknown status NCT01616342 Phase 4
21 Chlorthalidone and HCTZ Impacts on Platelet Activation Unknown status NCT02100462 Phase 4 Chlorthalidone 12.5 mg;Hydrochlorothiazide 25 mg;Aspirin 81 mg
22 Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF) Unknown status NCT02029534 Phase 4 Atorvastatin 20 mg;Atorvastatin 80 mg
23 Treatment of Facial Burns With Flammacerium Compared to Flammazine and the Impact of Facial Burns on Psychosocial Wellbeing Completed NCT00297752 Phase 4 ceriumnitrate silversulfadiazine (flammacerium);silversulfadiazine (flammazine)
24 The Effect of Two Versus Ten Days Application of Flammacerium in Partial Thickness Burns Completed NCT00156988 Phase 4 cerium nitrate-silver sulfadiazine (cerium-flamazine)
25 Pharmacokinetics Ertapenem Burns Completed NCT01497990 Phase 4 Ertapenem
26 Comparative Analysis of Cost-effectiveness of Silver Dressing in Burns Completed NCT02108535 Phase 4 Nanocrystalline silver;Silver Sulphadiazine
27 Efficacy and Safety Study of rhGM-CSF Gel to Treat Deep 2nd Thickness Burn Completed NCT01785784 Phase 4 rhGM-CSF Gel
28 Comparison of Wound Bed Establishment in Facial Burns Completed NCT01668030 Phase 4 Enzymatic agent;Bacitracin
29 Continuous Lidocaine Infusion for Management of Perioperative Burn Pain Completed NCT02059902 Phase 4 Lidocaine
30 Comparison of a Water-soluble Topical Antimicrobial to Silver Sulfadiazine in Partial Thickness Burns Completed NCT01926392 Phase 4 water-soluble therapy;silver sulfadiazine
31 Evaluation of Post Burn Rehabilitation Population for Itch Control Completed NCT00782054 Phase 4
32 An Acellular Epithelial Skin Substitute in Deep Partial-thickness Burns Completed NCT01454310 Phase 4
33 Effect of Early Enteral Tube Feeding Nutrition With an Immune Enhancing Diet in Severe Burn Patients Completed NCT00561210 Phase 4
34 Caustic Esophageal Burns in Children and High Doses of Methylprednisolone Completed NCT02002078 Phase 4 methylprednisolon
35 Low-dose Hydrocortisone in Acutely Burned Patients Completed NCT00149123 Phase 4 hydrocortisone 200 mg/day
36 Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants Completed NCT00859547 Phase 4
37 Open, Prosp, Rand. Invest. Evaluating Pain With Mepitel One vs.Bridal Veil and Staples on Split Thickness Skin Grafts Completed NCT01365273 Phase 4
38 Ethnic Differences in Response to Topical Capsaicin: A Psychophysical Study on Healthy Subjects Completed NCT00655811 Phase 4 Capsaicin;Placebo moisturizing cream
39 Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin Completed NCT01139047 Phase 4 metronidazole 1% gel;azelaic acid 15% gel
40 Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin Completed NCT01139008 Phase 4 metronidazole 1% gel;azelaic acid 15% gel
41 Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel Completed NCT01522456 Phase 4 Epiduo Gel;Retin-A Micro Microsphere 0.1%
42 A Clinical Trial to Study the Effects of Two Drugs, Lycopene and Prednisolone in Patients With Oral Lichen Planus Completed NCT02587117 Phase 4 lycopene;Prednisolone
43 Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face Completed NCT00919191 Phase 4 Tretinoin gel;Adapalene and Benzoyl peroxide
44 Aruba Aloe Formula F-BC-096 in the Treatment of Split Thickness Donor Site After Wound Closure Completed NCT01213420 Phase 4
45 A Study of Sertraline to Prevent PTSD Completed NCT00182078 Phase 4 Placebo;Sertraline
46 Effect of Topically-Applied Hyaluronic-Acid on Palatal Epithelial Wound Closure Completed NCT02534415 Phase 4 Periodontal dressing material;0.2% Hyaluronic acid gel;0.8% Hyaluronic acid gel
47 Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration Completed NCT01161563 Phase 4 Triptorelin pamoate;Leuprolide acetate
48 "TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM Completed NCT00402012 Phase 4 Pioglitazone
49 Randomized Trial of Two Ablation Catheters in Paroxysmal Atrial Fibrillation Completed NCT00678340 Phase 4
50 Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy Completed NCT03091569 Phase 4

Search NIH Clinical Center for Burns

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Burns cell therapies at LifeMap Discovery.

Genetic Tests for Burns

Anatomical Context for Burns

MalaCards organs/tissues related to Burns:

41
Skin, Eye, Testes, Breast, Lung, Brain, Spinal Cord
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Burns:
# Tissue Anatomical CompartmentCell Relevance
1 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Burns

Articles related to Burns:

(show top 50) (show all 2471)
# Title Authors Year
1
A successful approach to conrol burning mouth syndrome using matricaria recutita and cognitive therapy. ( 29849976 )
2018
2
An increase in salivary flow with amitriptyline may indicate treatment resistance in burning mouth syndrome. ( 29575764 )
2018
3
Catastrophizing, pain and traumatic stress symptoms following burns: A prospective study. ( 29436110 )
2018
4
Treatment Strategies for Hypopigmentation in the Context of Burn Hypertrophic Scars. ( 29464168 )
2018
5
The role of psychological factors in the development of burning mouth syndrome. ( 29074062 )
2018
6
Platelet count: A predictor of sepsis and mortality in severe burns; Methodological issues. ( 29395399 )
2018
7
Platelet-Rich Plasma Injection in Burn Scar Areas Alleviates Neuropathic Scar Pain. ( 29483815 )
2018
8
The Use of Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome in Severe Burns Without Inhalation Injury. ( 29901798 )
2018
9
Course and Predictors of Pruritus Following Burns: A Multilevel Analysis. ( 29963682 )
2018
10
Medical Folk Remedy: Two Cases of Garlic Burns. ( 29931078 )
2018
11
Management of reticular oral lichen planus patients with burning mouth syndrome-like oral symptoms: a pilot study. ( 29308937 )
2018
12
Epigallocatechin gallate inhibits corneal neovascularization in ratalkaline burn model. ( 29731448 )
2018
13
Depression and distress in burning mouth syndrome: A case control study. ( 29460523 )
2018
14
Understanding of Burning Mouth Syndrome Based on Psychological Aspects. ( 29507908 )
2018
15
Fifteen-minute consultation: Childhood burns: inflicted, neglect or accidental. ( 29934360 )
2018
16
Clinical characterization and treatment outcome of patients with burning mouth syndrome. ( 29714699 )
2018
17
Emergency management of burns: part 2. ( 29969203 )
2018
18
Burn Scar Evaluation Using the CutometerAr MPA 580 in Comparison to "Patient and Observer Scar Assessment Scale" and "Vancouver Scar Scale". ( 29596600 )
2018
19
Plasma IL-8 signature correlates with pain and depressive symptomatology in patients with burning mouth syndrome: Results from a pilot study. ( 29194773 )
2018
20
Sildenafil Therapy in Patients With Digital Burns and Raynaud's Syndrome. ( 29931173 )
2018
21
Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature. ( 29706950 )
2018
22
Targeted sequencing of burn scar-related squamous cell carcinomas identified PIK3CA amplification. ( 29941200 )
2018
23
Melatonin Treatment in Patients with Burning Mouth Syndrome: A Triple-Blind, Placebo-Controlled, Crossover Randomized Clinical Trial. ( 29694465 )
2018
24
Evaluation of laser therapy and alpha-lipoic acid for the treatment of burning mouth syndrome: a randomized clinical trial. ( 29502160 )
2018
25
Workforce Planning to Sustain UK Burns Services. ( 29398079 )
2018
26
Tetramethylpyrazine in a Murine Alkali-Burn Model Blocks NFI_B/NRF-1/CXCR4-Signaling-Induced Corneal Neovascularization. ( 29801148 )
2018
27
Multicenter Randomized Controlled Trial to Assess an e-Learning on Acute Burns Management. ( 29931302 )
2018
28
Carbon Monoxide and Cyanide Poisoning in the Burned Pregnant Patient: An Indication for Hyperbaric Oxygen Therapy. ( 29461288 )
2018
29
Is burning mouth syndrome a neuropathic pain condition? ( 29257770 )
2018
30
A pragmatic evidence-based clinical management algorithm for burning mouth syndrome. ( 29750091 )
2018
31
Preclinical assessment of safety and efficacy of intravenous delivery of autologous adipose-derived regenerative cells (ADRCs) in the treatment of severe thermal burns using a porcine model. ( 29958745 )
2018
32
MicroRNA-296 mediated corneal neovascularization in an animal model of corneal burns after alkali exposures. ( 29399058 )
2018
33
Mechanical sensitivity and psychological factors in patients with burning mouth syndrome. ( 29777310 )
2018
34
Assessment of quality-of-life in patients with face-and-neck burns: The Burn-Specific Health Scale for Face and Neck (BSHS-FN). ( 29958746 )
2018
35
Treatment of corneal chemical alkali burns with a crosslinked thiolated hyaluronic acid film. ( 29429747 )
2018
36
Metastatic "Burned Out" Seminoma Causing Neurological Paraneoplastic Syndrome-Not Quite "Burned Out". ( 29441039 )
2018
37
History of burning mouth syndrome (1800-1950): A review. ( 29569416 )
2018
38
Dystrophic calcinosis cutis within burns, successfully treated with excision and secondary intention wound healing. ( 29430689 )
2018
39
Changes in the vibration sensitivity and pressure pain thresholds in patients with burning mouth syndrome. ( 29782537 )
2018
40
Plasma N-acylethanolamine and endocannabinoid levels in burning mouth syndrome: potential role in disease pathogenesis. ( 29436743 )
2018
41
Autonomic nerve activity indexed using 24-h heart rate variability in patients with burns. ( 29409672 )
2018
42
Spectral Doppler findings in a rare case of acute compartment syndrome following leg burn. ( 29904471 )
2018
43
Patient satisfaction after fractional ablation of burn scar with 2940nm wavelength Erbium-Yag laser. ( 29627130 )
2018
44
Spurious thrombocytosis in the setting of hemolytic anemia and microcytosis secondary to extensive burn injury. ( 29391327 )
2018
45
Hyperkalemia in electrical burns: A retrospective study in Colombia. ( 29395406 )
2018
46
Saliva on the oral mucosa and whole saliva in women diagnosed with burning mouth syndrome. ( 29917294 )
2018
47
A Rare Extraskeletal Osteosarcoma Appearing After 55 Years on a Large Stage 3 Burn Scar. ( 29971170 )
2018
48
Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Adipose Tissue, and Dental Pulp as Sources of Cell Therapy for Zone of Stasis Burns. ( 29442525 )
2018
49
A 20-year (1996-2015) trend in deaths as a result of burns in the Transkei subregion of South Africa. ( 29958507 )
2018
50
Physical activity and sedentary behavior following pediatric burns - a preliminary investigation using objective activity monitoring. ( 29449948 )
2018

Variations for Burns

Expression for Burns

Search GEO for disease gene expression data for Burns.

Pathways for Burns

Pathways related to Burns according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.77 ALB CRH INS TTR
2 12.52 HGF IL1B INS TNF
3
Show member pathways
12.2 CSF2 IL1B TNF
4
Show member pathways
12.08 CSF2 IL1B TNF
5
Show member pathways
12 ALB IL1B INS TNF
6 11.84 ALB HGF INS
7 11.76 HGF IL1B TNF
8 11.72 CSF2 IL1B TNF
9 11.66 CSF2 IL1B TNF
10 11.64 CSF2 IL1B TNF
11 11.59 CSF2 IL1B TNF
12 11.48 CSF2 IL1B TNF
13
Show member pathways
11.38 CSF2 IL1B TNF
14 11.19 CSF2 IL1B TNF
15 11.15 IL1B TNF
16 11.14 IL1B TNF
17 11.12 HGF IL1B TNF
18 11.1 IL1B TNF
19 11.08 IL1B TNF
20 10.98 ALB INS TTR
21 10.91 IL1B TNF
22 10.76 IL1B TNF
23 10.72 CSF2 HGF IL1B TNF
24 10.61 CSF2 IL1B TNF

GO Terms for Burns

Cellular components related to Burns according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 ALB CRH CSF2 HGF IL1B INS
2 extracellular space GO:0005615 9.28 ALB CRH CSF2 HGF IL1B INS

Biological processes related to Burns according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.85 CRH CSF2 HGF IL1B INS
2 cytokine-mediated signaling pathway GO:0019221 9.84 CSF2 HGF IL1B TNF
3 positive regulation of cell migration GO:0030335 9.8 HGF IL1B INS
4 cellular protein metabolic process GO:0044267 9.78 ALB INS SERPINC1 TTR
5 positive regulation of protein kinase B signaling GO:0051897 9.77 HGF INS TNF
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.76 IL1B INS TNF
7 positive regulation of gene expression GO:0010628 9.72 CRH CSF2 IL1B INS TNF
8 positive regulation of protein phosphorylation GO:0001934 9.67 CRH HGF IL1B TNF
9 positive regulation of phagocytosis GO:0050766 9.64 IL1B TNF
10 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.64 IL1B TNF
11 lipopolysaccharide-mediated signaling pathway GO:0031663 9.63 IL1B TNF
12 positive regulation of cytokine secretion GO:0050715 9.62 INS TNF
13 positive regulation of interleukin-8 production GO:0032757 9.62 IL1B TNF
14 negative regulation of interleukin-6 production GO:0032715 9.61 HGF TNF
15 positive regulation of mitotic nuclear division GO:0045840 9.61 IL1B INS
16 regulation of protein secretion GO:0050708 9.59 INS TNF
17 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.58 IL1B TNF
18 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.58 CSF2 IL1B TNF
19 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.57 IL1B TNF
20 positive regulation of podosome assembly GO:0071803 9.56 CSF2 TNF
21 activation of MAPK activity GO:0000187 9.56 HGF IL1B INS TNF
22 positive regulation of chemokine biosynthetic process GO:0045080 9.55 IL1B TNF
23 regulation of establishment of endothelial barrier GO:1903140 9.52 IL1B TNF
24 positive regulation of fever generation GO:0031622 9.51 IL1B TNF
25 sequestering of triglyceride GO:0030730 9.49 IL1B TNF
26 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.43 IL1B TNF
27 MAPK cascade GO:0000165 9.35 CSF2 HGF IL1B INS TNF
28 negative regulation of lipid catabolic process GO:0050995 9.33 IL1B INS TNF
29 regulation of signaling receptor activity GO:0010469 9.1 CSF2 HGF IL1B INS TNF TTR

Molecular functions related to Burns according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 CSF2 IL1B TNF
2 hormone activity GO:0005179 9.33 CRH INS TTR
3 protease binding GO:0002020 9.13 INS SERPINC1 TNF
4 identical protein binding GO:0042802 9.1 ALB HGF INS SERPINC1 TNF TTR

Sources for Burns

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....